4.8 Article Proceedings Paper

Bile acid transporter-mediated oral drug delivery

期刊

JOURNAL OF CONTROLLED RELEASE
卷 327, 期 -, 页码 100-116

出版社

ELSEVIER
DOI: 10.1016/j.jconrel.2020.07.034

关键词

Oral drug delivery; Bile acid; Enterohepatic circulation; Transporter; ASBT; Lymphatic delivery

资金

  1. National Institute of Health [NIH DK114015]

向作者/读者索取更多资源

Bile acids are synthesized in the liver, stored in the gallbladder, and secreted into the duodenum at meals. Apical sodium-dependent bile acid transporter (ASBT), an ileal Na+-dependent transporter, plays the leading role of bile acid absorption into enterocytes, where bile acids are delivered to basolateral side by ileal bile acid binding protein (IBABP) and then released by organic solute transporter OST alpha/beta. The absorbed bile acids are delivered to the liver via portal vein. In this process called enterohepatic recycling, only 5% of the bile acid pool (similar to 3 g in human) is excreted in feces, indicating the large recycling capacity and high transport efficacy of ASBT-mediated absorption. Therefore, bile acid transporter-mediated oral drug delivery has been regarded as a feasible and potential strategy to improve the oral bioavailability. This review introduces the key factors in enterohepatic recycling, especially the mechanism of bile acid uptake by ASBT, and the development of bile acid-based oral drug delivery for ASBT-targeting, including bile acid-based prodrugs, bile acid/drug electrostatic complexation and bile acid-containing nanocarriers. Furthermore, the specific transport pathways of bile acid in enterocytes are described and the recent finding of lymphatic delivery of bile acid-containing nanocarriers is discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据